(Q81227747)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

editorial

0 references

title

Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference

1 reference

2

Daniel Aletaha

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Josef S Smolen

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

publication date

6 May 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Rheumatology

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

296-297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0813

7 January 2021

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0813

7 January 2021

The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0813

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0813

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0813

7 January 2021

Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0813

7 January 2021

Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0813

7 January 2021

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0813

7 January 2021

Comparative effectiveness of treatments for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0813

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0813

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18461061%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference